Progyny, Inc. (NASDAQ:PGNY) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lessened its stake in Progyny, Inc. (NASDAQ:PGNY – Get Rating) by 24.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 413,874 shares of the company’s stock after selling 133,029 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.45% of Progyny worth $15,340,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Arizona State Retirement System grew its position in shares of Progyny by 2.0% during the 3rd quarter. Arizona State Retirement System now owns 19,989 shares of the company’s stock valued at $741,000 after buying an additional 384 shares during the last quarter. TownSquare Capital LLC boosted its holdings in shares of Progyny by 13.7% in the second quarter. TownSquare Capital LLC now owns 12,367 shares of the company’s stock valued at $359,000 after acquiring an additional 1,493 shares in the last quarter. Bessemer Group Inc. boosted its holdings in shares of Progyny by 7.3% in the third quarter. Bessemer Group Inc. now owns 92,195 shares of the company’s stock valued at $3,416,000 after acquiring an additional 6,258 shares in the last quarter. Barclays PLC boosted its holdings in shares of Progyny by 321.4% in the third quarter. Barclays PLC now owns 15,819 shares of the company’s stock valued at $586,000 after acquiring an additional 12,065 shares in the last quarter. Finally, Natixis bought a new position in shares of Progyny in the second quarter valued at approximately $587,000. Institutional investors and hedge funds own 86.12% of the company’s stock.

Insider Buying and Selling at Progyny

In other Progyny news, Chairman David J. Schlanger sold 1,285 shares of the stock in a transaction on Tuesday, January 31st. The shares were sold at an average price of $35.00, for a total value of $44,975.00. Following the completion of the sale, the chairman now directly owns 74,716 shares of the company’s stock, valued at approximately $2,615,060. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Chairman David J. Schlanger sold 1,285 shares of the firm’s stock in a transaction dated Tuesday, January 31st. The shares were sold at an average price of $35.00, for a total transaction of $44,975.00. Following the completion of the transaction, the chairman now directly owns 74,716 shares of the company’s stock, valued at approximately $2,615,060. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Norman Payson sold 6,617 shares of the firm’s stock in a transaction dated Wednesday, December 21st. The stock was sold at an average price of $31.65, for a total transaction of $209,428.05. Following the transaction, the director now directly owns 279,063 shares of the company’s stock, valued at $8,832,343.95. The disclosure for this sale can be found here. Insiders sold a total of 222,433 shares of company stock valued at $7,945,078 in the last ninety days. Company insiders own 14.00% of the company’s stock.

Progyny Stock Performance

Progyny stock opened at $34.37 on Thursday. The firm has a market cap of $3.21 billion, a PE ratio of 114.57 and a beta of 1.56. The firm’s 50 day moving average price is $33.04 and its two-hundred day moving average price is $35.95. Progyny, Inc. has a twelve month low of $25.67 and a twelve month high of $53.10.

Progyny (NASDAQ:PGNY – Get Rating) last released its quarterly earnings data on Monday, February 27th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.01. Progyny had a net margin of 3.86% and a return on equity of 9.24%. The firm had revenue of $214.32 million for the quarter, compared to analyst estimates of $211.78 million. During the same quarter in the prior year, the business earned $0.15 EPS. The company’s revenue for the quarter was up 68.0% compared to the same quarter last year. Equities analysts anticipate that Progyny, Inc. will post 0.27 EPS for the current fiscal year.

Analyst Ratings Changes

PGNY has been the subject of several recent analyst reports. SVB Leerink reiterated a “market perform” rating and issued a $34.00 price objective (down from $59.00) on shares of Progyny in a report on Thursday, January 5th. JPMorgan Chase & Co. decreased their price objective on shares of Progyny from $78.00 to $62.00 and set an “overweight” rating for the company in a report on Friday, November 18th. Finally, KeyCorp decreased their price objective on shares of Progyny from $55.00 to $45.00 and set an “overweight” rating for the company in a report on Monday, December 19th. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Progyny presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.25.

About Progyny

(Get Rating)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.